Identification of Novel Targetable Kinases in SR-a GvHD
- Conditions
- Graft Versus Host Disease
- Registration Number
- NCT04342442
- Lead Sponsor
- University of Freiburg
- Brief Summary
In this study, the investigators aim to identify novel targetable kinases in SR-a GvHD patient samples and investigate their role in different immune cell subtypes.
- Detailed Description
Corticosteroids are the first-line treatment of a GvHD, however many patients do not respond to corticosteroids. Patients with steroid-refractory a GvHD (SR-a GVHD) have a low 1-year survival rate. In this study, the investigators aim to identify and validate novel targetable kinases in SR-a GvHD patient peripheral blood mononuclear cells (PBMCs) by using a kinase-specific proteomic approach, and thereafter to investigate the role of the identified kinases in different immune cell subtypes by analyzing biopsies taken from SR- a GvHD patients.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
- allo-transplanted
- confirmed diagnosis of a GvHD
- age ≥ 18 years
- peripheral blood samples and biopsies available
- written informed consent
- ability to understand the nature of the study and the study-related procedures and to comply with them
- age < 18 years
- lack of informed consent
- patients that cannot be classified in one of the 2 groups (steroid-refractory, steroid-responsive)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of differentially regulated kinases 3 years Bead-based Kinase Assay enrichment (Knet beads) of PBMC lysates
- Secondary Outcome Measures
Name Time Method Analysis of protein expression 3 years Analysis of PBMC lysates by western blot
Analysis of immune cell subtype 3 years Immunohistochemistry of intestinal biopsies